The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection

Medical Mycology

Volumn 48, Issue 2, 2010, Pages 436-439

  Kludze Forson, Maabo ^a   Eschenauer, Gregory A ^b   Kubin, Christine J ^b   Della Latta, Phyllis ^b   Lam, Simon W ^c  

^a ST VINCENT S HOSPITAL   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antifungals; Candida; Candidemia; Fluconazole; Initiation

Indexed keywords

AMPHOTERICIN; CASPOFUNGIN; FLUCONAZOLE; HYPERTENSIVE FACTOR; VORICONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN;

ADULT; AGED; ANTIFUNGAL SUSCEPTIBILITY; ANTIMICROBIAL THERAPY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CONTROLLED STUDY; DRUG PREFERENCE; FEMALE; FUNGUS CULTURE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; THERAPY DELAY; ANALYSIS OF VARIANCE; APACHE; CANDIDA; CANDIDIASIS; DRUG ADMINISTRATION; FUNGEMIA; MIDDLE AGED; NONPARAMETRIC TEST; TREATMENT OUTCOME; VERY ELDERLY;

CANDIDA;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; APACHE; CANDIDA; CANDIDIASIS; DRUG ADMINISTRATION SCHEDULE; ECHINOCANDINS; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 76649102736     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903208256     Document Type: Article

References (11)

1. Garey KW, Rege M, Pai MP, et al.. Timeto initiation offluconazoletherapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31 .
2. Klevay MJ, Ernst EJ, Hollanbaugh JL, et al.. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2008; 60: 273-277 .
3. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-3645 .
4. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60: 613-618 .
5. Baddley JW, Patel M, Bhavnani SM, Moser SA, Andes DR. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008; 52: 3022-3028 .
6. Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005; 49: 3171-3177 .
7. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007; 51: 35-39 .
8. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-447.
9. Rodriguez-Tudela JL, Almirante B, Rodriguez-Pardo D, et al.. Correlation of the MIC and dose/MIC ratio of fluconazoleto thetherapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 2007; 51: 3599-3604 .
10. Clinical Laboratory Standards Institute (CLSI) . Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard, 3rd edn , CLSI document M27-A3 edn . Wayne PA : CLSI ; 2008 .
11. McGregor JC, Rich SE, Harris AD, et al.. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 2007; 45: 329-337 .